Clinical trials: Bleeding Disorder
Hemophilia A
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
This study is a multi-center, open-label, single-arm trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (≥12 years old) with severe hemophilia A who…
- Trial name
- NCT03815318
- Testing
- Recombinant Human Coagulation FVIII
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sinocelltech Ltd.
Coagulation Disorder
Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.
Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world .
- Trial name
- NCT04479280
- Testing
- Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Brain Injuries
Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury
The study's objective is to evaluate the effectiveness and safety of tranexamic acid for adult patients with moderate to severe TBI.With the research question as "Does TXA reduce the incidence of progressive intracranial…
- Trial name
- NCT00755209
- Testing
- tranexamic acid
- Where
- Thailand
- Volunteers
- 238 people
- Sponsor
- Khon Kaen University
Hemophilia A
Individualizing Hemophilia Prophylaxis Using Thromboelastography
Currently dosing for prophylaxis is not individualized, and the general approach is to use a dose of 25-40 units/kg given 3 times per week or every other day.
- Trial name
- NCT02582060
- Testing
- Thromboelastography/Thromboelastometry-Guided Treatment Regimen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital Los Angeles
Hemorrhagic Disorders, Bleeding Disorder of Unknown Cause
Bleeding Disorder of Unknown Cause in the Netherlands
The purpose of the Bleeding Disorder of Unknown Cause in the Netherlands study (BDUC-iN) is to learn more about unexplained bleeding in individuals with a bleeding disorder of unknown cause (BDUC).
- Trial name
- BDUC-iN (NCT07454161)
- Where
- 8 sites in Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University Medical Center
Dental Caries, Bleeding on Probing
Evaluating Methods of Dental Health Instructions on the Oral Health Indices of 12-18-year-old Patients With Fixed Orthodontics
The goal of this clinical trial is to learn which type of oral health education works best to help 12-18-year-old participants with fixed orthodontic appliances (braces) keep their mouths healthy.
- Conditions
- Dental Caries, Bleeding on Probing, Gingival Index, Plaque Index
- Trial name
- NCT07667283
- Testing
- Verbal Oral Hygiene Instruction, Pamphlet-Based Oral Hygiene Instruction, Video-Based Oral Hygiene Instruction
- Where
- Iran
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
- Trial name
- NCT03219723
- Testing
- Vonoprazan, Amoxicillin hydrate, Clarithromycin
- Where
- Japan
- Volunteers
- 560 people
- Sponsor
- Takeda
Von Willebrand Disease, Type 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been…
- Trial name
- WILL-EMI (NCT06998524)
- Testing
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates
- Where
- 29 sites in United States, Belgium and 12 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Blood Coagulation Disorders
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures
This study will compare patients with mild to moderate prolongation of the INR test who receive FFP infusions prior to invasive hepatobiliary procedures for bleeding complications to patients who do not receive FFP infusions.
- Trial name
- NCT00233246
- Testing
- FFP Infusion
- Where
- 15 sites in United States
- Sponsor
- Massachusetts General Hospital
Hemophilia A
Hemophilia Inhibitor Previously Untreated Patient Study
Hemophilia A is a congenital bleeding disorder caused by deficiency of factor VIII (FVIII) and is treated by replacement therapy with FVIII concentrate.
- Trial name
- HIPS (NCT01652027)
- Testing
- FVIII concentrate
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center, Houston
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005641
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Kidney Diseases Receiving Anticoagulants
Frequency and Risk Factors of Bleeding in Patients With Chronic Kidney Disease Receiving Anticoagulants
1-Introduction: Chronic kidney disease (CKD) is a significant global public health issue, closely linked to cardiovascular disease (CVD).
- Trial name
- NCT06543927
- Testing
- serum creatinine, INR
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Factor XIII Deficiency
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII.
- Trial name
- NCT00885742
- Testing
- FXIII Concentrate (Human)
- Where
- 23 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- CSL Behring
Puerperal Sepsis, Postpartum Hemorrhage
Assessing Childbirth-related Complications at the Community Level in Kenya
Kenya is one of the countries in sub-Saharan Africa that still experience high maternal mortality. For instance, in 2008/09 maternal mortality ratio was estimated to be 488/100,000 live births.
- Conditions
- Puerperal Sepsis, Postpartum Hemorrhage, Preeclampsia and Eclampsia, Retained Placenta, Without Hemorrhage
- Trial name
- NCT01665456
- Where
- Kenya
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Wilson Liambila
Peptic Ulcer
Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy
To evaluate if intravenous PPI infusion, when administered prior to endoscopy, hastens resolution of bleeding stigmata and thereby facilitates endoscopic examinations and reduces the need for endoscopic treatment.
- Trial name
- NCT00164866
- Testing
- Omeprazole
- Where
- China
- Volunteers
- 638 people
- Sponsor
- Chinese University of Hong Kong
Heavy Menstrual Bleeding, Bleeding Disorder
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes…
- Conditions
- Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
- Trial name
- HMB-BD (NCT05916469)
- Testing
- Levonorgestrel Intrauterine System, Norethindrone Acetate
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- Oregon Health and Science University
Tbi, Intracranial Edema
Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI
Traumatic brain injury (TBI) is the most common cause of acquired disability in youth and a source of significant morbidity and family burden.
- Conditions
- Tbi, Intracranial Edema, Brain Edema, Craniocerebral Trauma
- Trial name
- NCT02368366
- Testing
- Therapist Guided Face to Face Family Problem Solving, Therapist Guided Online Family Problem Solving, Self-Guided Online Family Problem Solving
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hemophilia
EPOCH-Economics and Patient Outcomes in China in Haemophilia
The overarching goal of the EPOCH project is to: Support a broad and robust needs assessment in the haemophilia space in China Measure the variability in the needs and care provision Generate outcome data (health economic…
- Trial name
- EPOCH (NCT07454239)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hemophilia A
Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
This NIS aims to assess the patient-reported outcomes (PROs) in enrolled subjects
- Trial name
- NCT02718677
- Testing
- Refacto AF
- Sponsor
- Pfizer
Hemophilia A
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
Hemophilia A is an inherited blood disorder in which one protein, Factor VIII, needed to form blood clots is missing or not present in sufficient levels.
- Trial name
- NCT01775618
- Testing
- BAY94-9027
- Where
- 37 sites in United States, Argentina and 15 more
- Volunteers
- 73 people
- Sponsor
- Bayer